{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"704.9","upperLimit":"2300.1","value":"1273.3"},{"groupId":"OG001","lowerLimit":"1658.9","upperLimit":"2925.6","value":"2203.0"},{"groupId":"OG002","lowerLimit":"3741.5","upperLimit":"6118.8","value":"4784.7"}]}],"title":"Anti-HPV 6 (N=11, N=21, N=22)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1096.3","upperLimit":"3618.2","value":"1991.6"},{"groupId":"OG001","lowerLimit":"1940.8","upperLimit":"3388.3","value":"2564.3"},{"groupId":"OG002","lowerLimit":"2964.4","upperLimit":"5188.0","value":"3921.6"}]}],"title":"Anti-HPV 11 (N=11, N=21, N=22)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1558.5","upperLimit":"3640.4","value":"2381.9"},{"groupId":"OG001","lowerLimit":"2982.6","upperLimit":"5262.4","value":"3961.8"},{"groupId":"OG002","lowerLimit":"5493.9","upperLimit":"10196.1","value":"7484.4"}]}],"title":"Anti-HPV 16 (N=11, N=23, N=24)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"284.8","upperLimit":"1135.7","value":"568.7"},{"groupId":"OG001","lowerLimit":"966.4","upperLimit":"1958.2","value":"1375.7"},{"groupId":"OG002","lowerLimit":"1453.4","upperLimit":"3688.3","value":"2315.3"}]}],"title":"Anti-HPV 18 (N=11, N=24, N=24)"},{"categories":[{"measurements":[{"comment":"The lower bound of the 95% confidence interval is below the level of detectability (\\<8).","groupId":"OG000","lowerLimit":"NA","upperLimit":"79.1","value":"24.3"},{"groupId":"OG001","lowerLimit":"1502.4","upperLimit":"2763.0","value":"2037.5"},{"groupId":"OG002","lowerLimit":"3282.4","upperLimit":"6967.5","value":"4782.3"}]}],"title":"Anti-HPV 31(N=11, N=24, N=23)"},{"categories":[{"measurements":[{"comment":"The lower bound of the 95% confidence interval is below the level of detectability (\\<4).","groupId":"OG000","lowerLimit":"NA","upperLimit":"52.7","value":"10.8"},{"groupId":"OG001","lowerLimit":"760.8","upperLimit":"1429.1","value":"1042.8"},{"groupId":"OG002","lowerLimit":"1329.7","upperLimit":"3368.8","value":"2116.5"}]}],"title":"Anti-HPV 45 (N=11, N=26, N=25)"},{"categories":[{"measurements":[{"comment":"The lower and upper bounds of the 95% confidence interval are below the level of detectability (\\<16 to \\<16).","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"1798.6","upperLimit":"3561.9","value":"2531.1"},{"groupId":"OG002","lowerLimit":"2997.7","upperLimit":"6145.2","value":"4292.0"}]}],"title":"Anti-HPV 52 (N=9, N=23, N=25)"},{"categories":[{"measurements":[{"comment":"The lower bound of the 95% confidence interval is below the level of detectability (\\<6).","groupId":"OG000","lowerLimit":"NA","upperLimit":"86.1","value":"17.7"},{"groupId":"OG001","lowerLimit":"1276.5","upperLimit":"2424.4","value":"1759.2"},{"groupId":"OG002","lowerLimit":"2335.4","upperLimit":"4428.8","value":"3146.4"}]}],"title":"Anti-HPV 58 (N=10, N=24, N=22)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"30"}],"units":"Participants"}],"description":"The quadrivalent HPV (GARDASIL™) vaccine has types 6, 11, 16, 18, and the octavalent HPV has types 6, 11, 16, 18, 31, 45, 52, and 58. Serum antibody titres to the HPV type were obtained using a competitive Luminex immunoassay (cLIA) after vaccination with GARDASIL™ or the octavalent HPV vaccine. GMTs were calculated and are reported as the antibody concentration in milli-Merck Units per milliliter (mMU/mL) of neutralizing monoclonal antibody equivalent.","dispersionType":"95% Confidence Interval","groups":[{"description":"Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) for Phase A","id":"OG000","title":"qHPV (GARDASIL™) - Phase A Control"},{"description":"Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and 15 mcg ISCOMATRIX™(IMX)","id":"OG001","title":"Octavalent HPV With 15 mcg IMX / AAHS"},{"description":"Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and 30 mcg ISCOMATRIX™ (IMX)","id":"OG002","title":"Octavalent HPV With 30 mcg IMX / AAHS"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Per Protocol Immunogenicity (PPI) population: participants who were not protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 and polymerase chain reaction (PCR)-negative Day 1 through Month 7 for the relevant HPV type(s), had a valid Month 7 serology result collected in the appropriate day range.","reportingStatus":"POSTED","timeFrame":"4 weeks postdose 3 (Phase A)","title":"Geometric Mean Titers (GMTs) to Each of the HPV Types Contained in the Vaccine for Phase A","type":"PRIMARY","unitOfMeasure":"mMU/mL"}